Furthermore, it was shown that BRAFV600E-driven tumors lacking miR-31 maintained better differentiation and showed improved uptake of 131I. Using nanoparticle-mediated administration of an anti-miR-31 antagomir, the authors demonstrated that blocking miR-31 slowed tumor growth and enhanced the uptake of 131I in tumors from TPO-CreERT2/BrafCA mice. This evidence concerns the gene TPO and neoplasm.